CRC Research Update — August 27, 2026
Today's colorectal cancer research highlights
liver-mets
A collection of 60 issues
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
Skip to content
The CRC Digest
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer
CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 23, 2026
Today's colorectal cancer research highlights
Study compares biologic agents in liver-limited RAS wild-type disease
Skip to content
The CRC Digest
▸ TREATMENT
Study compares biologic agents in liver-limited RAS wild-type disease
A retrospective analysis of 241 patients with RAS wild-type metastatic colorectal cancer confined to the liver compared outcomes among patients treated with first-line chemotherapy plus panitumumab, cetuximab, or bevacizumab, evaluating depth of response, objective
Study identifies risk factors for irinotecan liver toxicity
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Study identifies risk factors for irinotecan liver toxicity
A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology)
This content
CRC Research Update — August 20, 2026
Today's colorectal cancer research highlights
Australian registry study examines treatment patterns in early-onset CRC with liver metastases
Skip to content
The CRC Digest
◇ RESEARCH
Australian registry study examines treatment patterns in early-onset CRC with liver metastases
A retrospective cohort study using the TRACC registry explored treatment timing, sequencing, and outcomes for early-onset CRC patients (≤50 years) with liver-only metastases compared to late-onset patients. (Med J Aust)
This
CRC Research Update — August 14, 2026
Today's colorectal cancer research highlights
KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC
A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic